EP Patent

EP3046557A1 — Rock in combination with mapk-pathway

Assigned to Netherlands Cancer Institute · Expires 2016-07-27 · 10y expired

What this patent protects

The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibi…

USPTO Abstract

The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of ROCK and proteins of the MAPK/ERK-pathway in the treatment of KRAS-, NRAS- or BRAF- mutated cancer, in particular in NRAS mutated melanoma.

Drugs covered by this patent

Patent Metadata

Patent number
EP3046557A1
Jurisdiction
EP
Classification
—
Expires
2016-07-27
Drug substance claim
No
Drug product claim
No
Assignee
Netherlands Cancer Institute
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.